Peeking Into The Nature Of AAV Production Using HEK293 In A Perfusion Process

VintaBio, a contract manufacturing organization (CMO), has developed a proprietary method for AAV vector production known as VintaProcess™ — a scalable, cost-effective platform designed to meet the growing needs of gene therapy manufacturing. This approach combines a high-performing, adherent HEK293 cell line (VintaCell™), optimized transfection reagents (VintaFect™), fixed-bed bioreactor technology, and a carefully refined culture process. Central to VintaProcess is the principle that maintaining anchorage-dependent cells in their native, adherent environment supports greater viability and cell health, which in turn enhances transfection efficiency and vector yield.

Unlike traditional transient transfection methods — often used in suspension or adherent cultures — which can overwhelm host cells and lead to high levels of empty capsids and residual impurities, VintaProcess allows for improved control over cell behavior and vector kinetics. The fixed-bed system enables physical separation between the host cells and the circulating media, facilitating a unique opportunity to observe AAV production over time through timed fractional harvests. By collecting supernatant at defined intervals, VintaBio was able to monitor vector yield dynamics and assess the continued productivity of host cells throughout the culture period.

To further evaluate the durability and performance of the system beyond the industry-standard 72-hour production window, VintaBio extended culture durations to 5 and 7 days. This allowed for deeper insight into the longevity and productivity of VintaCells, and how the platform performs over prolonged operation — key data for supporting commercial-scale applications.

Access the full application note to explore the detailed results and advantages of the VintaProcess platform.